Fourth report of the biological therapy element of the UK IBD audit
Thursday, 24 September 2015 14:32
Latest UK IBD audit report shows further improvement for patients following treatment with biological therapies
The UK inflammatory bowel disease (IBD) clinical audit report reveals today that the majority of patients (80% adult and 77% paediatric) with Crohn's disease saw an improvement following biological therapies
This is the fourth report of the biological therapy element of the UK IBD audit. The purpose of this audit is to measure the efficacy, safety and appropriate use of the biological therapies infliximab and adalimumab, also known as anti-TNFα drugs, in patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at intervals during their treatment.
The data presented in the reports demonstrate that biological therapies for IBD are effective and relatively safe treatments. Patterns of use are changing, with earlier use in patients with less severe disease. It is likely that this reflects more appropriate prescribing as physicians become more familiar with these drugs.
National and executive summary versions of both adult and paediatric reports are available on the Royal College of Physicians' website:
NICE guidance on the use of vedolizumab in Crohn's disease
Wednesday, 26 August 2015 08:53
Single Technology Appraisal (STA) - Vedolizumab for the treatment of adult patients with moderately to severely active Crohn's disease [ID690]
The Final Guidance will be published on the NICE website: http://www.nice.org.uk/guidance/indevelopment/gid-tag461 on 26th August 2015. There will also be a version of the guidance available for people using services, carers and the public called 'Information for the public'. Additionally, the documentation used to develop the guidance such as the underpinning evidence submissions, will remain on the website.
A copy of the guidance is available for you to download from NICE Docs: https://appraisals.nice.org.uk/request/7289
"The BSG welcomes the publication of this guidance on the use of Vedolizumab in Crohn's disease. A significant number of patients suffering from Crohn's disease fail to benefit from anti-TNF therapy, and for them the availability of a drug therapy that has a completely different mode of action, with good trial evidence of efficacy and safety is most welcome."
Dr AB Hawthorne,
IBD section chairman
Independent Cancer Taskforce Report
Monday, 27 July 2015 11:27
The Independent Cancer Taskforce has published its report, Achieving world-class cancer outcomes: a strategy for England 2015-2020. This report sets out recommendations for a new cancer strategy for England. An Executive Summary and press release are also available.
The Chair of the Taskforce, Harpal Kumar, sets out the opportunities to transform cancer services in a letter to the Chief Executives of the bodies responsible for running the NHS, and on the Cancer Research UK blog.
NHSIQ Productive Endoscopy
Tuesday, 14 July 2015 14:50
The Productive Endoscopy Unit is a set of 'how to' guides to help staff make improvements in endoscopy services and meet the quality improvement elements of the Global Rating Scale, and accreditation of service. The series is endorsed by the Joint Advisory Group for Gastrointestinal Endoscopy (JAG).
Based on the principles and methodology of 'Productive Operating Theatre' the series will help units to reduce waste through better workplace organisation; offering support processes; guidance for scheduling processes and improvement of information and patient flow - leading to reductions in errors and delays. The Productive Endoscopy Unit is available free of charge (one per unit) to all NHS endoscopy provider organisations and will be available from 1 April 2015. To pre-order your free copy, please fill in the details at the following link:
Page 10 of 13